SIERRA Trial Delivers Initial Data for Older Patients With AML
Rajneesh Nath, MD, discusses the early results of the phase III SIERRA trial investigating the efficacy of Iomab-B and protocol-specified allogeneic hematopoietic stem cell transplant versus the standard of care in older patients with active, relapsed or refractory acute myeloid leukemia.
Rajneesh Nath, MD, a medical oncologist at the Banner MD Anderson Cancer Center, discusses the early results of the phase III SIERRA trial (NCT02665065) investigating the efficacy of Iomab-B and protocol-specified allogeneic hematopoietic stem cell transplant (HCT) versus the standard of care in older patients with active, relapsed or refractory acute myeloid leukemia (AML).
Nath says that the safety of the Iomab-B, a reduced intensity conditioning regimen, and HCT combination was 1 of the most important parts of this multicenter trial. The study investigators looked at data after half of the patients on the trial were randomized. Thus far, they have reported that about 80% of the patients in the Iomab-B arm were unable to undergo transplant. They also had fully engrafted neutrophils and platelets.
In the conventional arm, about 20% of patients were able to undergo the standard-of-care transplant. However, this study allowed patients who did not go into remission to crossover from convention chemotherapy to the HCT and Iomab-B regimen, which was about 80% of patients, according to Nath.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
November 13th 2023In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
Read More
